The selected features were musculoskeletal conditions (β = 1.95), antidiabetic treatment regimen involving both oral hypoglycemic agents and insulin injections (β = 1.66), antidiabetic treatment regimen with oral hypoglycemic agents alone (β = −0.03), hyperlipidemia (β = 1.17), HbA1c (β = 0.86), neurological conditions (β = 0.85), hypertension (β = 0.24), FPG levels within the range of 7–8 mmol/L (β = −0.12), BMI (β = 0.09), sex (β = 0.05), and diastolic blood pressure (DBP; β = 0.02). This evidence concerns the gene INS and hyperlipidemia.